By Fineline Cube 
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing total revenues increased by 0.87% year-on-year (YOY) to RMB 70.763 billion (USD 9.7 billion). Within this, the pharmaceutical industry and pharmaceutical business achieved sales of RMB 5.885 billion (USD 808.74 million) and RMB 6.4878 billion (USD 8.916 billion), respectively.
Net Profit and Sector Performance
During the quarter, net profit attributable to shareholders of the listed company decreased by 13.56% YOY to RMB 1.333 billion (USD 183.2 million). The industrial sector, commercial sector, and major subsidiaries contributed profits of RMB 532 million (USD 73 million), RMB 834 million (USD 115 million), and RMB 196 million (USD 27 million), respectively. The net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was RMB 1.263 billion (USD 174 million).
Research and Development Investment
During the reporting period, Shanghai Pharmaceuticals invested RMB 612 million (USD 84 million) in research and development, underscoring its commitment to innovation and growth.
Business Segment Performance
The company maintained growth momentum in several key areas during the quarter:
- Import Agents: Sales revenue from the import general agency business reached RMB 8.6 billion (USD 1.3 billion) after a 9.0% expansion.
- Innovative Drug Services: The innovative pharmaceutical business achieved sales revenue of RMB 12.5 billion (USD 1.7 billion), up 23.2% YOY.
- CSO and Equipment Business: The drug CSO business revenue increased by 9.89% YOY. The sales revenue of the equipment health business reached RMB 10.9 billion (USD 1.5 billion), up 6.9% YOY.-Fineline Info & Tech